Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
uzansertib
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Uzansertib is an orally administered, selective, ATP-competitive pan-PIM serine/threonine kinase inhibitor developed by Incyte. It inhibits PIM1, PIM2, and PIM3, suppressing phosphorylation of downstream substrates involved in malignant-cell survival and proliferation. In the Medical College of Wisconsin phase Ib study, uzansertib was evaluated with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma. ([guidetopharmacology.org](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10626&tab=refs))
- Other names
- INCB-053914INCB053914INCB 053914
02
Targets
PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)RPS6KA3 (RSK2)PIM2 (Proto-oncogene serine/threonine-protein kinase Pim2)PASK (Per-arnt-sim kinase)
Beyond the preview
Go deeper on uzansertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on uzansertib.